NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News, & Analysis

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals declared that its Board of Directors has authorized a stock repurchase plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 3.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's management believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, October, 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.74 by $0.28. The biopharmaceutical company earned $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. Alexion Pharmaceuticals's revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.44 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Wednesday, October, 24th. The company provided earnings per share (EPS) guidance of $7.45-7.60 for the period, compared to the Thomson Reuters consensus estimate of $7.24. The company issued revenue guidance of $4.02-4.05 billion, compared to the consensus revenue estimate of $4.04 billion.Alexion Pharmaceuticals also updated its FY 2018 guidance to $7.45-7.60 EPS.

18 equities research analysts have issued twelve-month price targets for Alexion Pharmaceuticals' stock. Their forecasts range from $123.00 to $190.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $163.1176 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Press coverage about ALXN stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

Some companies that are related to Alexion Pharmaceuticals include AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA) and Mylan (MYL).

Alexion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.46%), BlackRock Inc. (7.31%), Jennison Associates LLC (3.87%), Bank of New York Mellon Corp (1.19%), TIAA CREF Investment Management LLC (1.08%) and Iridian Asset Management LLC CT (1.06%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Banco Santander S.A., Bank of Montreal Can, Bank of New York Mellon Corp, AXA, Mitsubishi UFJ Trust & Banking Corp, Swedbank, TIAA CREF Investment Management LLC and Franklin Resources Inc.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, American Century Companies Inc., Iridian Asset Management LLC CT, First Trust Advisors LP, Wells Fargo & Company MN, Point72 Asset Management L.P. and Candriam Luxembourg S.C.A.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $118.62.

Alexion Pharmaceuticals has a market capitalization of $26.46 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

The official website for Alexion Pharmaceuticals is http://www.alexion.com.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]